Incretin Atlas › Trials › SELECT
SELECT
Semaglutide · Obesity + established CVD, no diabetes
Design
- Molecule(s)
- Semaglutide
- Population
- Obesity + established CVD, no diabetes
- Official title
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2018-10 → 2023-06
- Participants
- 17604
- Registry
- NCT03574597
Cardiovascular and kidney outcomes
SELECT semaglutide 2.4 mg vs placebo · Obesity + established CVD, no diabetes · n = 17604 · 2023 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary Primary composite: CV death, nonfatal MI, or nonfatal stroke (time to first event) | 0.80 | 0.72–0.90 | 569 vs 701 | verified |
| Cardiovascular death Death from cardiovascular causes (first confirmatory secondary endpoint) | 0.85 | 0.71–1.01 | 223 vs 262 | verified |
| All-cause death Death from any cause (third confirmatory secondary endpoint) | 0.81 | 0.71–0.93 | 375 vs 458 | verified |
| Myocardial infarction Nonfatal myocardial infarction only (supportive secondary endpoint); fatal MI not reported separately | 0.72 | 0.61–0.85 | 234 vs 322 | verified |
| Stroke Nonfatal stroke only (supportive secondary endpoint); fatal stroke not reported separately | 0.93 | 0.74–1.15 | 154 vs 165 | verified |
| Hospitalisation for heart failure Hospitalization or urgent medical visit for heart failure (supportive secondary endpoint) | 0.79 | 0.60–1.03 | 97 vs 122 | verified |
| CV death or worsening HF Heart failure composite: CV death or hospitalization or urgent medical visit for heart failure (second confirmatory secondary endpoint) | 0.82 | 0.71–0.96 | 300 vs 361 | verified |
| Kidney composite Nephropathy composite (supportive secondary): renal death, long-term renal replacement therapy, persistent eGFR <15, persistent 50% eGFR reduction, or persisten | 0.78 | 0.63–0.96 | 155 vs 198 | verified |
| Expanded MACE (MACE + revasc. + UA) Cardiovascular expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina leading to hospitalization | 0.80 | 0.73–0.87 | 873 vs 1074 | verified |
| New-onset diabetes Glycated hemoglobin level >=6.5% (glycemic threshold for diabetes) in a population without diabetes at baseline; patients randomized in error with baseline HbA1c >6.5% excluded (8800 vs 8797 analysed) | 0.27 | 0.24–0.31 | 306 vs 1059 | verified |
| Coronary revascularisation Coronary revascularization | 0.77 | 0.68–0.87 | 473 vs 608 | verified |
| Hospitalisation for unstable angina Unstable angina leading to hospitalization | 0.87 | 0.67–1.13 | 109 vs 124 | verified |
Verbatim quotes (12)
- 3-point MACE · Results, Efficacy End Points; Table 2
occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval [CI], 0.72 to 0.90
- Cardiovascular death · Results, Efficacy End Points; Table 2
occurred in 223 patients (2.5%) in the semaglutide group and in 262 patients (3.0%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.71 to 1.01; P=0.07
- All-cause death · Table 2
Death from any cause | 375 (4.3) | 458 (5.2) | 0.81 (0.71 to 0.93)
- Myocardial infarction · Table 2
Nonfatal myocardial infarction | 234 (2.7) | 322 (3.7) | 0.72 (0.61 to 0.85)
- Stroke · Table 2
Nonfatal stroke | 154 (1.7) | 165 (1.9) | 0.93 (0.74 to 1.15)
- Hospitalisation for heart failure · Table 2
Hospitalization or urgent medical visit for heart failure | 97 (1.1) | 122 (1.4) | 0.79 (0.60 to 1.03)
- CV death or worsening HF · Table 2
Heart failure composite end point§ | 300 (3.4) | 361 (4.1) | 0.82 (0.71 to 0.96)
- Kidney composite · Table 2
Nephropathy composite end point‖‖ | 155 (1.8) | 198 (2.2) | 0.78 (0.63 to 0.96)
- Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary end points
| Cardiovascular expanded composite end point∥ | 873 (9.9) | 1074 (12.2) | 0.80 (0.73 to 0.87) | NA |
- New-onset diabetes · Table 2, supportive secondary end points
| Glycated hemoglobin level ≥6.5%†† | 306 (3.5) | 1059 (12.0) | 0.27 (0.24 to 0.31) | NA |
- Coronary revascularisation · Table 2, supportive secondary end points
| Coronary revascularization | 473 (5.4) | 608 (6.9) | 0.77 (0.68 to 0.87) | NA |
- Hospitalisation for unstable angina · Table 2, supportive secondary end points
| Unstable angina leading to hospitalization | 109 (1.2) | 124 (1.4) | 0.87 (0.67 to 1.13) | NA |
Primary sources
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
- Novo Nordisk A/S. SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). ClinicalTrials.gov identifier NCT03574597. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03574597
How to cite this page
Medical Adviser's Group. Incretin Atlas: SELECT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/select/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.